Cell technologies in the treatment of rheumatic diseases
https://doi.org/10.14412/1995-4484-2019-685-692
Abstract
Rheumatic diseases are caused by chronic autoimmune processes that require long-term therapy, which leads to the formation of resistance to the drugs used. The search for new approaches to their treatment in recent years has been enriched with the use of cell therapy methods. They are considered in this review of the literature and include the transplantation of hematopoietic stem cells, mesenchymal stem (stromal) cells, the induction or administration of T-regulatory cells, tolerogenic dendritic cells. The paper discusses methods of obtaining cell products, their safety and clinical use in patients with systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and other rheumatic diseases, and treatment complications. Based on the analysis, the authors give the comparative characteristics of various types of tolerogenic cell therapy for rheumatic diseases and point out their advantages, disadvantages, and the specific features of clinical application.
About the Authors
N. F. Soroka
Belarusian State Medical University
Russian Federation
Competing Interests: not
Russian Federation
Nikolay Soroka
83, Dzerzhinsky Pr., Minsk, 220116
Competing Interests: not
M. P. Potapnev
Belarusian State Medical University; Republican Research and Practical Center of Transfusiology and Medical Biotechnologies
Belarus
Competing Interests: not
Belarus
83, Dzerzhinsky Pr., Minsk, 220116; 160, Dolginovsky Road, Minsk, 220053
Competing Interests: not
N. A. Martusevich
Belarusian State Medical University
Belarus
Competing Interests: not
Belarus
83, Dzerzhinsky Pr., Minsk, 220116
Competing Interests: not
References
1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-38. doi: 10.1016/S0140-6736(16)30173-8
2. Nasonov EL. Achievements in rheumatology in the XXI century. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):133-40 (In Russ.). doi: 10.14412/1995-4484-2014-133-140
3. Nasonov EL, Mazurov VI, Usacheva YuV, et al. Developments of Russian original biological agents for the treatment of immunoinflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):201-10 (In Russ.). doi: 10.14412/1995-4484-2017-201-210
4. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol. 2011;25:549-67. doi: 10.1016/j.berh.2011.10.004
5. Mosanya CH, Isaacs JD. Tolerising cellular therapies: what is the promise for autoimmune disease? Ann Rheum Dis. 2019;78:297-310. doi: 10.1136/annrheumdis-2018-214024
6. Alexander T, Bondanza A, Muraro PA, et al. SCT for severe autoimmune diseases: consensus guidelines of the European society for blood and marrow transplantation for immune monitoring and biobanking. Bone Marrow Transplant. 2015;50:173-80. doi: 10:1038/bmt.2014.251
7. Verburg RJ, Kruize AA, van den Hoogen FH, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum. 2001;44:754-60. doi: 10.1002/1529-0131(200104)44:4<754::AID-ANR131>3.0.CO;2-N
8. Moore J, Brooks P, Milliken S, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum. 2002;46:2301-9. doi: 10.1002/art.10495
9. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006;295:527-35. doi: 10.1001/jama.295.5.527
10. Traynor AE, Corbridge TC, Eagan AE, et al. Prevalence and reversibility of pulmonary dysfunction in refractory systemic lupus: improvement correlates with disease remission following hematopoietic stem cell transplantation. Chest. 2005;127:1680-9. doi: 10.1378/chest.127.5.1680
11. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis. 2001;60:577-84. doi: 10.1136/ard.60.6.577
12. Van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490-8. doi: 10.1001/jama.2014.6368
13. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35-47. doi: 10.1056/NEJMoa1703327
14. Van Wijk F, Roord ST, Vastert B, et al. Regulatory T cells in autologous stem cell transplantation for autoimmune disease. Autoimmunity. 2008;41:585-91. doi: 10.1080/08916930802200182
15. Snowden JA, Saccardi R, Allez M, et al. Haematopoietc SCT in severe autoimmune diseases: updated guidelines of the European group for blood and marrow transplantation. Bone Marrow Transplant. 2012;47:770-90. doi: 10.1038/bmt.2011.185
16. Mascarenhas S. Emerging use of stem cell transplants for systemic sclerosis. Med Res Arch. 2016;4(6):17. doi: 10.18103/mra.v4i6.714
17. Oyama Y, Barr WG, Statkute L, et al. Autologous non-myeloabla-tive hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant. 2007;40(6):549-55. doi: 10.1038/sj.bmt.1705782
18. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haematopoietic stem cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trials. Lancet. 2011;378(9790):498-506. doi: 10.1016/S0140-6736(11)60982-3
19. Burt RK, Han X, Gozdziak P, et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome. Bone Marrow Transplant. 2018;53:692-700. doi: 10.1038/s41409-018-0173-x
20. Swart JF, Delemarre EM, van Wijk F, et al. Progress and controversies in hematopoietic stem cell transplantation for autoimmune rheumatic disease. Nat Rev Rheumatol. 2017;13(4):244-56. doi: 10.1038/nrrheum.2017.7
21. Tyndall A. Hematopoietic stem cell transplantation for autoimmune diseases: more than just prolonged immunosuppression. Curr Opin Hematol. 2018;25(6):433-40. doi: 10.1097/M0H.0000000000000466
22. Farge D, Burt RK, Oliveira M-C. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant. 2017;52:1495-503. doi: 10.1038/bmt.2017.56
23. Maria ATJ, Maumus M, Le Quellec A, et al. Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis. Clin Rev Allerg Immunol. 2017;52:234-59. doi: 10.1007/s12016-016-8552-9
24. Fathollahi A, Gabalou NB, Aslani S. Mesenchymal stem cell transplantation in systemic lupus erythematosis, a mesenchymal stem cell disorder. Lupus. 2018;27(7):1053-64. doi: 10.1177/0961203318768889
25. Wang D, Zhang H, Liang J, et al. A long-term follow-up study of allogeneic mesenchymal stem/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus. Stem Cell Rep. 2018;10:933-41. doi: 10.1016/j.stemcr.2018.01.029
26. Gu F, Wang D, Zhang H, et al. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol. 2014;33(11):1611-9. doi: 10.1007/s10067-014-2754-4
27. Rubio-Rivas M, Royo C, Simeon CP, et al. Mortality and survival in systemic sclerosis: systemic review and meta-analysis. Semin Arthritis Rheum. 2014;44:208-19. doi: 10.1016/j.semar-trit.2014.05.010
28. Christopeit M, Schendel M, Foll J, et al. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stromal cells from an allogeneic halpoidentical-related donor mediated by ligation of CD137L. Leukemia. 2008;22(5):1062-4. doi: 10.1038/sj.leu.2404996
29. Keyszer G, Christopeit M, Fick S, et al. Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells for allogeneic related donors: report of five cases. Arthritis Rheum. 2011;63(8):2540-2. doi: 10.1002/art.30431
30. Granel B, Daumas A, Jouve E, et al. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis. 2015;74(12):2175-82. doi: 10.1136/annrheumdis-2014-205681
31. Daumas A, Magalon J, Jouve E, et al. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients. Curr Res Transl Med. 2017;65(1):40-3. doi: 10.1016/j.retram.2016.10.006
32. Rozier P, Maria A, Goulabchand R, et al. Mesenchymal stem cells in systemic sclerosis: allogenic or autologous approaches for therapeutic use? Front Immunol. 2018;9:art. 2983. doi: 10.3389/fmmi.2018.02938
33. Ghoryani M, Shariati-Sarabi Zh, Tavakkol-Afshari J, et al. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran. BiomedPharmacother. 2019;(2019):1834-40. doi: 10.1016/j.biopha.2018.11.056
34. Alvaro-Gracia JM, Jover JA, Garcia-Vicuna R, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, singleblind, placebo-controlled phase Ib/IIa clinical trial. Ann RheumatolDis. 2017;76(1):196-202. doi: 10.1136/annrheumdis-2015-208918
35. Wang P, Li Y, Huang L, et al. Effects and safety of allogenic mesenchymal stem cells intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: A 20 week clinical trial. Cell Transplant. 2013. doi: 10.3727/096368913X667727
36. Nasonov EL, Aleksandrova EN, Avdeeva AS, Rubtsov YuP. T regulatory cells in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):430-7 (In Russ.). doi: 10.14412/1995-4484-2014-430-437
37. Gol-Ara M, Jadidi-Niaragh F, Sadria R, et al. The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis. Arthritis. 2012;2012:805875. doi: 10.1155/2012/805875
38. Romano M, Fanelli G, Albany CJ, et al. Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity. Front Immunol. 2019;10:art. 43. doi: 10.3389/fimmu.2019.00043
39. Von Spee-Mayer C, Siegert E, Abdirama D, et al. Low dose interleukin-2 selectively correct regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2015;75(7):1407-15. doi: 10.1136/annrheumdis-2015-207776
40. Humrich JY, Riemekasten G. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr Opin Rheum. 2019;31(2):208-12. doi: 10.1097/BOR.0000000000000575
41. Potapnev MP. Cell apoptosis and its regulation by cytokines. Immunologiya. 2002;23(4):237-43 (In Russ.).
42. Koreth J, Ritz J, Tsokos GC, et al. Low-dose interleukin-2 in the treatment of autoimmune disease. Oncol Hematol Rev. 2014;10(2):157-63. doi: 10.17925/OHR.2014.10.2.157
43. Mizui M, Tsokos G. Low-dose LI-2 in the treatment of Lupus. Curr Rheum Rep. 2016;18:68. doi: 10.1007/s11926-016-0617-5
44. Rosenwzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-1 across 11 autoimmune diseases in a single, open clinical trail. Ann Rheum Dis. 2018, art 214229.
45. He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991-3. doi: 10.1038/nm.4148
46. Sheng-Xiao Z, Ziao-Wen M, Xiao-Qing L, et al. Low dose interleukin-2 combined with tocilizumab selectively increases regulatory T cells helping refractory rheumatoid arthritis patients achieve remission more rapidly. Ann Rheum Dis. 2017;76 Suppl. 2:839. doi: 10.1136/annrheumdis-2017-eular.3611
47. Dall'Era M, Pauli ML, Remedios K, et al. Adoptive regulatory T cell therapy in patient with systemic lupus erythematosus. Arthritis Rheum. 2018;71(3):431-40. doi: 10.1002/art.40737
48. Hilkens CMU, Isaacs JD. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin Exp Immunol. 2012;172:148-57. doi: 10.1111/cei.1203842
49. Thomas R, Street S, Ramnoruth N, et al. Safety and preliminary evidence of efficacy in a phase I clinical trial of autologous toleris-ing dendritic cells exposed to citrullinated peptides (Rheumavax) in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70 Suppl.3:169.
50. Benham H, Nel HJ, Law SCh, et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci TranslMed. 2015;7:290ra87. doi: 10.1126/scitranslmed.aaa9301
51. Bell GM, Anderson AE, Diboll J, et al. Autologous tolerogrnic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. 2017;76:227-34. doi: 10.1136/annrheumdis-2015-208456
52. Cheung TT, McInnes IB. Future therapeutic targets in rheumatoid arthritis? Semin Immunopathol. 2017;39:487-500. doi: 10.1007/s00281-017-0623-3
53. Ahmed MS, Bae Y-S. Dendritic cell-based immunotherapy for rheumatoid arthritis: from bench to bedside. Immune Network. 2016;16(1):44-51. doi: 10.4110/in.2016.16.16.1.44
Review
For citations:
Soroka N.F., Potapnev M.P., Martusevich N.A. Cell technologies in the treatment of rheumatic diseases. Rheumatology Science and Practice. 2019;57(6):685-692. (In Russ.) https://doi.org/10.14412/1995-4484-2019-685-692
Views:
982
Email this article 